Research ArticleDrug Discovery and Translational Medicine
Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain Metastases
Surabhi Talele, Wenjuan Zhang, Ju-Hee Oh, Danielle M. Burgenske, Ann C. Mladek, Sonja Dragojevic, Jann N. Sarkaria and William F. Elmquist
Journal of Pharmacology and Experimental Therapeutics June 2022, 381 (3) 217-228; DOI: https://doi.org/10.1124/jpet.121.001069
Surabhi Talele
Department of Pharmaceutics, Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.T., W.Z., J.-H.O., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.M.B., A.C.M., S.D., J.N.S.)
Wenjuan Zhang
Department of Pharmaceutics, Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.T., W.Z., J.-H.O., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.M.B., A.C.M., S.D., J.N.S.)
Ju-Hee Oh
Department of Pharmaceutics, Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.T., W.Z., J.-H.O., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.M.B., A.C.M., S.D., J.N.S.)
Danielle M. Burgenske
Department of Pharmaceutics, Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.T., W.Z., J.-H.O., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.M.B., A.C.M., S.D., J.N.S.)
Ann C. Mladek
Department of Pharmaceutics, Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.T., W.Z., J.-H.O., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.M.B., A.C.M., S.D., J.N.S.)
Sonja Dragojevic
Department of Pharmaceutics, Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.T., W.Z., J.-H.O., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.M.B., A.C.M., S.D., J.N.S.)
Jann N. Sarkaria
Department of Pharmaceutics, Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.T., W.Z., J.-H.O., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.M.B., A.C.M., S.D., J.N.S.)
William F. Elmquist
Department of Pharmaceutics, Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.T., W.Z., J.-H.O., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.M.B., A.C.M., S.D., J.N.S.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
CNS Delivery of the DNA-PKcs Inhibitor Peposertib
Surabhi Talele, Wenjuan Zhang, Ju-Hee Oh, Danielle M. Burgenske, Ann C. Mladek, Sonja Dragojevic, Jann N. Sarkaria and William F. Elmquist
Journal of Pharmacology and Experimental Therapeutics June 1, 2022, 381 (3) 217-228; DOI: https://doi.org/10.1124/jpet.121.001069
Research ArticleDrug Discovery and Translational Medicine
CNS Delivery of the DNA-PKcs Inhibitor Peposertib
Surabhi Talele, Wenjuan Zhang, Ju-Hee Oh, Danielle M. Burgenske, Ann C. Mladek, Sonja Dragojevic, Jann N. Sarkaria and William F. Elmquist
Journal of Pharmacology and Experimental Therapeutics June 1, 2022, 381 (3) 217-228; DOI: https://doi.org/10.1124/jpet.121.001069
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement